Needham & Company Starts Lexicon Pharmaceuticals (LXRX) at Buy; Valuation is Attractive
Tweet Send to a Friend
Needham & Company initiates coverage on Lexicon Pharmaceuticals (NASDAQ: LXRX) with a Buy. PT $3.
Needham analyst says, "Lexicon has ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "Lexicon has ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
